APA (7th ed.) Citation

AK, M., S, U., M, S., B, H., P, A., PJ, G., & M, Å. (2024). From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics, 116(3), 653. https://doi.org/10.1002/cpt.3362

Chicago Style (17th ed.) Citation

AK, Mercier, Ueckert S, Sunnåker M, Hamrén B, Ambery P, Greasley PJ, and Åstrand M. "From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials." Clinical Pharmacology and Therapeutics 116, no. 3 (2024): 653. https://doi.org/10.1002/cpt.3362.

MLA (9th ed.) Citation

AK, Mercier, et al. "From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials." Clinical Pharmacology and Therapeutics, vol. 116, no. 3, 2024, p. 653, https://doi.org/10.1002/cpt.3362.